Merck stock
MRKNYSEMerck & Co., Inc., HealthcareISIN US58933Y1055
68Score 68 out of 100, Neutral
Price and trend
86 / 100
Price history
+61% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Since October 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 53).
The price is 6.1% below its 52-week high. Largest decline in 20 years: 65% (December 2007 to March 2009).
Chart figures for advanced users
- SMA 50$146.22
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$128.45
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)53
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$91.45
- The lowest closing price of the last twelve months.
- Resistance$156.45
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Merck & Co., Inc. belongs to the Drug Manufacturers (General) industry (United States) and, with a market value of $362.27B, is number 5 of 27 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $64.93B (up 1.2% year on year) and earnings of $18.25B (up 6.6%).
- For fiscal 2026, analysts expect on average revenue of $67.22B (up 3.5%) and adjusted earnings per share of $2.77 (down 69.1%).
Show more
- MEQIRI Score 68 out of 100 (Neutral): rank 164 of 702 in Healthcare, median 53.
- The P/E is 148.5 because earnings over the last twelve months collapsed; on the expected earnings of the next twelve months it is 18.2 (Drug Manufacturers (General) median 25.7). The P/E therefore does not count in the score.
- Our model puts fair value at $181.91, with the price 19% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow above 500% of earnings over the last 12 months.Fundamentals 85
- Analysts expect strong earnings growthUp 58.1% a year through 2028 (estimates from 14 analysts).Growth 51
- Reliable dividendNo dividend cut for over 56 years.Capital allocation 65
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are momentum and technical analysis, while profitability holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among the 100 largest stocks.
From 2016 to 2025, 4 in 100 such stocks fell 30% or more within a year, against a group average of 9 in 100.
What lowers it
- solid fundamentals
- very large company
- price near its 52-week high
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $139.93 and expensive above $259.87 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $148.67, at 7.8% it would be $232.02.
Valuation metrics
From the cash-flow model alone; after a one-off collapse in earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 4.8% on the twelve months before. Revenue has grown solidly since 2006, at about 6% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 72%, operating 36%, net 28%. Last 12 months: net 4%.
Debt & balance sheet
latest quarterMeaningfully leveraged, but the interest bill is comfortably covered.
Earnings
- Next earnings
- 2 Feb 2027in 81 days
- Last reported
- 29 Oct 2026EPS reported $2.49 (expected $2.09)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 3.9% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $2.77+4.1%
- Revenue
- $67.22B+0.2%
- Earnings per share
- $8.91−3.9%
- Revenue
- $69.42B−0.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +6.1%Merck raised and narrowed its 2026 revenue and EPS guidance to $66.8 to $67.3 billion revenue (3% to 4% growth) and $2.77 to $2.82 EPS.
“We now expect revenue to be between $66.8 billion and $67.3 billion representing growth of 3% to 4% including a positive impact from foreign exchange of approximately 1 percentage point using mid October rates.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $25.58M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Guindo ChirfiSale
13 Aug 2026, EVP, Access, Policy & Comms
- Shares
- 10,000
- Price
- $135.00
- Value
- $1.35M
- Zachary JenniferSale
12 Aug 2026, EVP, General Counsel
- Shares
- 80,315
- Price
- $133.46
- Value
- $10.72M
- DeLuca Richard R.Sale
12 Aug 2026, EVP&Pres, Merck Animal Heallth
- Shares
- 11,699
- Price
- $131.63
- Value
- $1.54M
Show 6 more
- DeLuca Richard R.Sale
11 Aug 2026, EVP&Pres, Merck Animal Heallth
- Shares
- 12,837
- Price
- $131.76
- Value
- $1.69M
- DeLuca Richard R.Sale
10 Aug 2026, EVP&Pres, Merck Animal Heallth
- Shares
- 20,784
- Price
- $130.43
- Value
- $2.71M
- DeLuca Richard R.Sale
6 Aug 2026, EVP&Pres, Merck Animal Heallth
- Shares
- 6,050
- Price
- $130.38
- Value
- $788,773
- Guindo ChirfiSale
6 Aug 2026, EVP, Access, Policy & Comms
- Shares
- 15,000
- Price
- $131.00
- Value
- $1.97M
- Maraldo David R.Sale
5 Aug 2026, EVP & Pres. MMD
- Shares
- 2,686
- Price
- $128.72
- Value
- $345,736
- Williams David MichaelSale
5 Aug 2026, EVP,Chief Info&Digital Officer
- Shares
- 34,705
- Price
- $128.77
- Value
- $4.47M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Merck
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 68
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- Eli LillyLLY $1.34T85
- Johnson & JohnsonJNJ $682.52B75
- AbbVieABBV $520.47B74
- Roche HoldingROP.SW $394.85B77
- NovartisNOVN.SW $304.26B75
- AstraZenecaAZN $285.95B73
- AmgenAMGN $252.64B76
- Gilead SciencesGILD $208.31B57
ETFs that hold Merck
Held by 155 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| WisdomTree US High Dividend UCITS ETF AccWTD9 | 6.44% | 0.29% | €182.46M |
| WisdomTree US Equity Income UCITS ETF EUR Hedged AccWTDY | 6.35% | 0.35% | €204.34M |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 5.41% | 0.15% | €599.59M |
Show 5 more
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 5.30% | 0.15% | €3.29B |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 5.30% | 0.12% | €1.39B |
| Xtrackers MSCI World Health Care UCITS ETF 1CXDWH | 3.94% | 0.25% | €4.12B |
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 3.39% | 0.18% | €839.61M |
| iShares MSCI USA Quality Dividend Advanced UCITS ETFQDVD | 3.03% | 0.35% | €794.64M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Fairly valued since 8 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.